Patients with ulcerative colitis (UC) and Crohn's disease (CD) are at increased risk for developing colorectal cancer (CRC), and this is believed to be a result of chronic inflammation. Although conclusive evidence is still missing, both epidemiological and experimental observations suggest that certain drugs used to treat inflammation, such as mesalazine, can reduce the incidence of colitis-associated CRC. Therefore, in recent years, several studies have been conducted to dissect the mechanisms by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular mechanisms that underlie the antineoplastic action of mesalazine. © 2008 The WJG Press. All rights reserved.

Stolfi, C., Pellegrini, R., Franze, E., Pallone, F., Monteleone, G. (2008). Molecular basis of the potential of mesalazine to prevent colorectal cancer. WORLD JOURNAL OF GASTROENTEROLOGY, 14(28), 4434-4439 [10.3748/wjg.14.4434].

Molecular basis of the potential of mesalazine to prevent colorectal cancer

Stolfi C.;PALLONE, FRANCESCO;MONTELEONE, GIOVANNI
2008-01-01

Abstract

Patients with ulcerative colitis (UC) and Crohn's disease (CD) are at increased risk for developing colorectal cancer (CRC), and this is believed to be a result of chronic inflammation. Although conclusive evidence is still missing, both epidemiological and experimental observations suggest that certain drugs used to treat inflammation, such as mesalazine, can reduce the incidence of colitis-associated CRC. Therefore, in recent years, several studies have been conducted to dissect the mechanisms by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular mechanisms that underlie the antineoplastic action of mesalazine. © 2008 The WJG Press. All rights reserved.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/12 - Gastroenterologia
English
Chemoprevention; Colorectal cancer; Cyclooxygenase-2; Epidermal growth factor receptor; Inflammatory bowel disease; Mesalazine; Wnt/β-catenin
Stolfi, C., Pellegrini, R., Franze, E., Pallone, F., Monteleone, G. (2008). Molecular basis of the potential of mesalazine to prevent colorectal cancer. WORLD JOURNAL OF GASTROENTEROLOGY, 14(28), 4434-4439 [10.3748/wjg.14.4434].
Stolfi, C; Pellegrini, R; Franze, E; Pallone, F; Monteleone, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/28751
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 28
social impact